# Similar Ibrutinib Efficacy Across ALPINE and ELEVATE-RR Trials in Relapsed/Refractory Chronic Lymphocytic Leukemia: Matching-Adjusted Indirect Comparison

Mazyar Shadman,¹ Alessandra Tedeschi,² Leyla Mohseninejad,³ Keri Yang,⁴ Nicole Lamanna,⁵ Sheng Xu,⁶ Aileen Cohen,⁴ Swetha Challagulla,⁴ Mei Xue,⁴ Rhys Williams,⁴ Susan M. O'Brien,⁻ Jennifer R. Brown,⁶ Constantine S. Tam⁶ ¹Fred Hutchinson Cancer Center, Seattle, WA, USA; ⁴BeiGene USA Inc, San Mateo, CA, USA; ⁴BeiGene (Beijing) Co, Ltd, Beijing, China;

# INTRODUCTION

- Bruton tyrosine kinase (BTK) inhibitors are currently widely used for the treatment of patients with chronic lymphocytic leukemia (CLL). Ibrutinib, the first BTK inhibitor approved for the treatment of CLL, was followed by the second-generation BTK inhibitor, acalabrutinib, and recently the next-generation BTK inhibitor, zanubrutinib<sup>1</sup>
- Both zanubrutinib and acalabrutinib were compared to ibrutinib in phase 3 randomized controlled trials (RCTs) in relapsed or refractory (R/R) CLL. In the ALPINE trial, zanubrutinib demonstrated superior progression-free survival (PFS) when compared with ibrutinib in the all-comer R/R CLL population, whereas the ELEVATE-RR trial showed noninferior PFS with acalabrutinib vs ibrutinib in patients with R/R CLL with the presence of del(17p) or  $del(11q)^{2,3}$
- Recent attempts to compare efficacy results in the ibrutinib arm across trials omitted patient characteristics that are critical for appropriate cross-trial comparisons<sup>4</sup>
- In the absence of head-to-head RCTs, indirect comparisons of treatments or common control arms across trials can be performed using matching-adjusted indirect comparison (MAIC) methodology. MAIC allows for robust comparison by reweighting individual patient data (IPD) from one study to the aggregated data of another to provide greater adjustment for observed trial differences vs conventional meta-analytic methods<sup>5</sup>
- The objective of this study was to compare efficacy in the ibrutinib control arm across ALPINE and ELEVATE-RR trials using a comprehensive MAIC methodology

# METHODS

• To obtain comparable populations for MAIC, the high-risk subgroup of patients from ALPINE (ie, patients with del[17p] or del[11q] mutations) was included in the analysis (Figure 1)

Figure 1. Overall Methodology

(Ibrutinib, n=325)

Individual patient data (Data cutoff: August 2022; median follow-up: 29.6 months)

Eligible population (High risk—del[17p]/[11q])

(Ibrutinib—del[17p]/[11q], n=123)

Individual patient data (Data cutoff: August 2022; median follow-up: 28.1 months)

ELEVATE-RR (Ibrutinib—del[17p]/[11q], n=265)



**ELEVATE-RR** 

(lbrutinib—del[17p]/[11q], n=265)

Published aggregate data

<sup>7</sup>Chao Family Comprehensive Cancer Center, University of California, Irvine, CA, USA; <sup>8</sup>Dana-Farber Cancer Institute, Boston, MA, USA; <sup>9</sup>Alfred Hospital and Monash University, Melbourne, VIC, Australia

Published aggregate data


## Variables included for matching

Serum β2-microglobulin Number of prior therapies Binet stage

## Matching and reweighting

Eligible individual patient data from ALPINE were matched and reweighted based on their similarity to the published population-leve profile of the ibrutinib arm of ELEVATE-RR.







## Outcome



HRs were estimated using weighted Cox proportional hazards regression model

Sensitivity: COVID-19 adjustment, additional matching of EMs and PFs EM, effect modifier; HR, hazard ratio; IGHV; immunoglobulin heavy chain variable; INV, investigator; IRC, independent review committee; PF, prognostic factor.

- IPD of the high-risk patients from the ibrutinib arm of ALPINE (median follow-up, 28.1 months) were adjusted to match the published population-level profile from the ibrutinib arm of ELEVATE-RR
- As there was no common comparator between the two trials when comparing ibrutinib arms, an unanchored MAIC was conducted
- The MAIC was designed to adjust for all relevant treatment effect modifiers (EMs), including immunoglobulin heavy chain variable status, del(17p), del(11q), TP53 status, serum β2-microglobulin, number of prior therapies, and Binet stage
- The ALPINE data cutoff of August 2022 was used, given the availability of both independent review committee (IRC)- and investigator (INV)-assessed data and the possibility of a comparison vs other recently published MAICs<sup>4</sup> (median follow-up, 29.6 months)
- Efficacy in the weighted population of the ibrutinib arm in ALPINE was compared with efficacy in the aggregated-level data of the ibrutinib arm in ELEVATE-RR (median follow-up, 40.9 months)
- After the population adjustment, the hazard ratio (HR) obtained by weighted Cox proportional hazards model was applied to assess PFS and overall survival (OS) outcomes. PFS was analyzed as per IRC and INV
- Given that the ALPINE trial was conducted during the COVID-19 period and ELEVATE-RR follow-up data included in the analysis were prior to the COVID-19 pandemic, a sensitivity analysis was conducted by adjusting the ALPINE PFS and OS for COVID-19 impact by censoring patients who died due to COVID-19 at the most recent disease assessment prior to death or at death due to COVID-19
- A few scenarios were included to adjust for other possible EMs and prognostic factors (PFs), such as age, sex, complex karyotype, bulky disease, and Eastern Cooperative Oncology Group (ECOG) performance status

# RESULTS

### **Baseline Characteristics**

• The high-risk population in ALPINE included 123 patients in the ibrutinib arm, who were matched against aggregated data from 265 patients in the ibrutinib arm of the ELEVATE-RR trial (**Table 1**)

Table 1. Baseline Characteristics of High-Risk Population in Ibrutinib Arm of ALPINE Before Matching to Ibrutinib Arm of **ELEVATE-RR** 

Baseline Characteristics	High-risk Ibrutinib Arm ALPINE Trial (n=123)	Ibrutinib Arm ELEVATE-RR Trial (n=265)
Age, median, years	68	65
Age ≥75 years, %	22.8	16.2
Male, %	70.7	73.2
Mutated IGHV, %	17.4	10.6
Del(17p), del(11q), and mutated <i>TP53</i> , %	4.9	7.5
Del(17p), no del(11q), and mutated <i>TP53</i> , %	11.4	29.1
Del(17p), no del(11q), and unmutated <i>TP53</i> , %	17.1	4.9
Del(17p), del(11q), and unmutated <i>TP53</i> , %	7.3	3.8
No del(17p), del(11q), and unmutated <i>TP53</i> , %	55.3	49.1
No del(17p), del(11q), and mutated <i>TP53</i> , %	4.1	5.7
β2-microglobulin >3.5 mg/L, %	69.2	80.8
Binet stage A (CLL only), %	9.3	11.6
Binet stage B (CLL only), %	56.8	42.6
No. of prior therapies ≥4, %	8.1	10.6
Bulky disease (LDi ≥5 cm), %	50.4	51.3
Complex karyotype (≥3 abnormalities), %	46.5	47.2
ECOG PS 2, %	3.3	8.3
Del(17p), %	40.7	45.3
Del(11q), %	71.5	66.1
TP53 mutation, %	20.3	42.3

## **Matched Variables**

- Table 2 provides a comprehensive summary of EMs and PFs that were adjusted in the base-case and sensitivity analyses
- Of note, the effective sample size (ESS) in model M4 was very small as it was the full adjusted model

Table 2. A Summary of Treatment Effect Modifiers and Prognostic Factors Adjusted in the Base-Case and Sensitivity


Population Characteristics	M1 (Base-Case) ESS=63	M2 ESS=64	M3 ESS=55	M4 ESS=25	M5 ESS=64	M6 ESS=81
Age ≥75 vs <75 years			✓	<b>√</b>		
Male			✓	✓		
Mutated IGHV	✓	<b>√</b>	✓	✓	✓	✓
Del(17p) mutation	✓	<b>√</b>	✓	✓	<b>✓</b>	✓
Del(11q) mutation	✓	<b>√</b>	✓	✓		
TP53 mutation	✓	<b>√</b>	✓	✓	✓	
Complex karyotype (≥3 abnormalities)				✓		
β2-microglobulin (>3.5 mg/L)	✓	<b>√</b>	✓	✓	✓	✓
No. of prior therapies	✓		✓	✓	✓	✓
Bulky disease (LDi ≥5 cm)			<b>✓</b>	✓		
ECOG PS 2 vs 0/1			✓	✓		
Binet stage Δ and B (CLL only)		$\checkmark$				<b>√</b>


ECOG PS, Eastern Cooperative Oncology Group performance status; ESS, effective sample size; IGHV, immunoglobulin heavy chain variable; LDi, longest diameter.

### **Efficacy Outcomes**

- After population adjustment (median follow-up, 28.4 months), no statistically significant differences were observed in ALPINE ibrutinib vs ELEVATE ibrutinib in PFS-IRC (HR, 0.80; 95% CI, 0.49-1.28; *P*=.3485) and PFS-INV (HR, 1.18; 95% CI, 0.75-1.86; *P*=.4827) (**Figure 2**)
- No statistically significant differences were noted in ALPINE ibrutinib vs ELEVATE ibrutinib in terms of OS (HR, 0.91; 95% CI, 0.50-1.65; *P*=.7539)

Figure 2. Comparing PFS-IRC (A) and PFS-INV (B) in Ibrutinib Arms Across ALPINE and ELEVATE-RR





## CONCLUSIONS

- Using a comprehensive list of matching variables, this MAIC compared the performance of ibrutinib across ALPINE and ELEVATE-RR trials and did not show any significant difference in the performance of ibrutinib across the 2 trials
- Results of this study were robust across multiple sensitivity analyses

#### **Sensitivity Analysis**

- Sensitivity analysis with COVID-19 adjustment yielded similar results as the main analysis (**Table 3**)
- Scenario matching for additional treatment EMs and PFs also generated results consistent with the main analysis (Table 3)

Table 3. Results of Sensitivity Analyses (HRs Presented as Ibrutinib ALPINE vs Ibrutinib ELEVATE-RR)

Model	Ibrutinib ESS	Adjustment for COVID-19	PFS-IRC HR (95% CI); <i>P</i> -value	PFS-INV HR (95% CI); <i>P</i> -value	OS HR (95% CI); <i>P</i> -value
⁄Л1 (base-case)	63 -	No	0.80 (0.49-1.28); <i>P</i> =.3485	1.18 (0.75-1.86); <i>P</i> =.4827	0.91 (0.50-1.65); <i>P</i> =.7539
		Yes	0.74 (0.45-1.22); <i>P</i> =.2362	1.11 (0.69-1.77); <i>P</i> =.6710	0.73 (0.37-1.43); <i>P</i> =.3567
/12	C 4	No	0.78 (0.48-1.26); <i>P</i> =.3080	1.15 (0.73-1.82); <i>P</i> =.5438	0.89 (0.49-1.62); <i>P</i> =.7110
	64	Yes	0.72 (0.44-1.19); <i>P</i> =.2025	1.08 (0.67-1.74); <i>P</i> =.7459	0.71 (0.36-1.40); <i>P</i> =.3260
ИЗ	FF	No	0.71 (0.41-1.22); <i>P</i> =.2141	1.05 (0.63-1.75); <i>P</i> =.8573	0.74 (0.36-1.53); <i>P</i> =.4212
	55 -	Yes	0.67 (0.38-1.18); <i>P</i> =.1679	1.00 (0.59-1.70); <i>P</i> =.9899	0.63 (0.28-1.42); <i>P</i> =.2684
Л4	25	No	0.96 (0.51-1.82); <i>P</i> =.9045	1.08 (0.54-2.14); <i>P</i> =.8309	0.77 (0.29-2.07); <i>P</i> =.6055
	25	Yes	0.90 (0.46-1.76); <i>P</i> =.7631	1.00 (0.49-2.05); <i>P</i> =.9990	0.63 (0.20-1.95); <i>P</i> =.4204
<b>1</b> 15	C 4	No	0.82 (0.51-1.32); <i>P</i> =.4135	1.20 (0.77-1.90); <i>P</i> =.4217	0.97 (0.53-1.76); <i>P</i> =.9141
	64 -	Yes	0.76 (0.47-1.25); <i>P</i> =.2863	1.13 (0.71-1.81); <i>P</i> =.5996	0.78 (0.40-1.53); <i>P</i> =.4752
//6	81 -	No	0.83 (0.53-1.29); <i>P</i> =.3990	1.31 (0.86-2.00); <i>P</i> =.2021	1.07 (0.61-1.87); <i>P</i> =.8146
		Yes	0.76 (0.48-1.21); <i>P</i> =.2540	1.24 (0.80-1.90); <i>P</i> =.3379	0.87 (0.47-1.62); <i>P</i> =.6577

ESS, effective sample size; HR, hazard ratio; INV, investigator; IRC, independent review committee

## DISCUSSION

- Comparing the common-comparator arms of 2 trials (ibrutinib vs ibrutinib) instead of the different investigational arms (zanubrutinib vs acalabrutinib) allows for eliminating some of the residual confounding that is inherent in MAICs
- The ibrutinib arms of ALPINE and ELEVATE-RR were very similar with regard to PFS and OS
- Both INV and IRC measure of PFS were similar between ibrutinib in ALPINE and ibrutinib in ELEVATE-RR PFS-INV and -IRC had opposite numerical trends, observed across all sensitivity analysis
- Despite decreased estimated sample size due to considering a comprehensive list of variables in the adjustment, results were consistent across multiple scenarios tested
- While MAIC provides a basis for testing hypotheses with regard to treatment efficacy across trials, the ultimate evidence of relative efficacy must be sought within RCTs

## REFERENCES

1. Eyre TA, Riches JC. Cancers. 2023;15:2596. 2. Brown JR, et al. *N Engl J Med.* 2023;388:319-332.

3. Byrd JC, et al. *J Clin Oncol*. 2021;39:3441-3452.

4. Ghia P, et al. *Hemasphere*. 2023;7(suppl):e78258de. 5. Signorovitch JE, et al. Value Health. 2012;15(6):940-947.

6. Kittai AS, et al. Am J Hematol. 2023. doi: 10.1002/ajh.27110.

### ACKNOWLEDGMENTS

The authors would like to thank the investigators, site support staff, and especially the patients for participating in this study. This study was sponsored by BeiGene, Ltd. Editorial assistance was provided by ConnectHEOR and Nucleus Global, an Inizio Company, and was supported by BeiGene.

#### DISCLOSURES MS: Consultancy: AbbVie, Genentech, AstraZeneca, Pharmacyclics, BeiGene, BMS, MorphoSys/Incyte, Kite, Eli Lilly, Genmab, Mustang Bio, Regeneron, ADC

therapeutics, Fate Therapeutics, Janssen and MEI Pharma; Research funding: Mustang Bio, Bristol Myers Squibb, Pharmacyclics, Genentech, AbbVie, TG Therapeutics, BeiGene, AstraZeneca, Genmab, Morphosys/Incyte, Vincerx. AT: Consultancy: BeiGene, AstraZeneca, AbbVie, Janssen; Honoraria: BeiGene, AstraZeneca, AbbVie, Janssen; Speakers bureau: BeiGene, AstraZeneca, AbbVie, Janssen; Travel, accommodations, expenses: BeiGene, AstraZeneca, AbbVie, Janssen. **NL**: Consultancy: AbbVie, AstraZeneca, BeiGene, Lilly/Loxo, Genentech, Janssen, Pharmacyclics; Research funding: AbbVie, AstraZeneca, BeiGene, Lilly/Loxo, Genentech, Octapharma, Oncternal, MingSight. SMO: Consultancy: AbbVie, AstraZeneca, BeiGene, Lilly, Janssen, Johnson & Johnson, Pfizer, Pharmacyclics; Research Funding: BeiGene, Lilly, Pfizer, Pharmacyclics, Regeneron; Membership: CLL Society (unpaid). JRB: Consultancy: AbbVie, Acerta/AstraZeneca, Alloplex Biotherapeutics, BeiGene, Lilly Genentech/Roche, Grifols Worldwide Operations, Hutchmed, iOnctura, Kite, Merck, MEI Pharma, Numab Therapeutics, Pfizer, Pharmacyclics; Research funding: BeiGene, Gilead, iOnctura, Loxo/Lilly, MEI Pharma, SecuraBio, TG Therapeutics. LM, KY, SX, AC, SC, MX, RW: Employment: BeiGene. CST: Research funding: Janssen, AbbVie, BeiGene; Honoraria: Janssen, AbbVie, BeiGene, Loxo, Novartis, Roche.